Physician profile
Emily Stuart
NPI 1871065201
$1,447.11
in general payments reported to CMS, 2019-2025
21 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.56 | 2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $149.43 | 2025 | Mounjaro, Jardiance |
| Pfizer INC. | $148.84 | 2025 | |
| Glaxosmithkline, LLC. | $103.35 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $76.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.75 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70.10 | 2025 | |
| Lundbeck LLC | $68.07 | 2025 | Rexulti |
| Novo Nordisk INC | $58.70 | 2025 | Rybelsus, Ozempic |
| Tolmar, INC. | $55.05 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $54.51 | 2025 | Lagevrio |
| Exact Sciences Corporation | $49.05 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Corium, LLC | $48.26 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $47.36 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $44.82 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.33 | 2025 | Trintellix |
| Antares Pharma, INC. | $36.62 | 2025 | Xyosted |
| Corcept Therapeutics | $24.33 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $17.47 | 2025 | Spravato |
| Amgen INC. | $16.25 | 2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $14.15 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.